Etrasimod
Etrasimod，也被称为APD334，是一种多功能S1P1受体的功能拮抗剂，用于治疗多发性硬化症(MS)和其他自身免疫性疾病的下一代治疗药物。
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Etrasimod |
|---|---|
| Iupac 化学名称 | (R)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid |
| 同义词 | APD334 ; APD-334 ; APD 334 ; Etrasimod |
| 英文同义词 | APD334 ; APD-334 ; APD 334 ; Etrasimod |
| 分子式 | C26H26F3NO3 |
| 分子量 | 457.49321 |
| Smile | C1(CCCC1)C1=C(C=C(COC2=CC=3C4=C(NC3C=C2)[C@H](CC4)CC(=O)O)C=C1)C(F)(F)F |
| InChiKey | MVGWUTBTXDYMND-QGZVFWFLSA-N |
| InChi | InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1 |
| Cas号 | 1206123-37-6 |
| 相关CAS号 | 1206123-37-6 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 类白色至白色固体 |
|---|---|
| 纯度 | 99.73% |
| 存储 | 短期可在0-4度保存，数天至数月；长期可在-20度保存三年。 |
| 可溶性 | 可溶于DMSO |
| 处理方式 | Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation. |
| 运输条件 | 可在常温下运输 |
| 海关编码 |
| Targets | S1P receptor modulator |
|---|---|
| Mechanism | Etrasimod is an oral, selective S1P1, S1P4, and S1P5 receptor modulator. Sphingosine 1-phosphate (S1P) is a membrane-derived lysophospholipid signaling molecule involved in regulation of multiple physiologic and pathophysiologic processes, mediated through the 5 isoforms of the G protein–coupled S1P receptor (S1P1 through S1P5). |
| Cell study | |
| Animal study | Etrasimod (1 mg/kg, i.v.) decreases peripheral lymphocytes in mouse, rat, dog, and monkey (IC50s = 101, 51, 58, and 98 nM, respectively). It delays or prevents the onset and severity of murine experimental autoimmune encephalomyelitis (EAE) when administered at 0.3, 1, or 3 mg/kg. It also leads to lower EAE disease scores relative to vehicle when administered after disease onset and is efficacious in a rat model of collagen-induced arthritis. |
| Clinical study | Phase 3 |
1: Buzard DJ, Kim SH, Lopez L, Kawasaki A, Zhu X, Moody J, Thoresen L, Calderon
I, Ullman B, Han S, Lehmann J, Gharbaoui T, Sengupta D, Calvano L, Montalban AG,
Ma YA, Sage C, Gao Y, Semple G, Edwards J, Barden J, Morgan M, Chen W, Usmani K,
Chen C, Sadeque A, Christopher RJ, Thatte J, Fu L, Solomon M, Mills D, Whelan K,
Al-Shamma H, Gatlin J, Le M, Gaidarov I, Anthony T, Unett DJ, Blackburn A, Rueter
J, Stirn S, Behan DP, Jones RM. Discovery of APD334: Design of a Clinical Stage
Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Med Chem
Lett. 2014 Nov 4;5(12):1313-7. doi: 10.1021/ml500389m. eCollection 2014 Dec 11.
PubMed PMID: 25516790; PubMed Central PMCID: PMC4265817.
